Last updated: February 1, 2026
Summary
Etelcalcetide (brand name: Parsabiv) is an injectable calcimimetic developed by Amgen to manage secondary hyperparathyroidism (SHPT) in patients undergoing dialysis. This report synthesizes recent clinical trial developments, assesses current market dynamics, and provides future projections based on ongoing research, regulatory pathways, and market trends. Notably, etelcalcetide's approval in multiple regions, including the US and EU, has driven its commercial trajectory. The drug faces competitive pressures from alternatives like cinacalcet and emerging therapies, but its clinical profile and regulatory endorsements position it prominently within this segment.
Clinical Trials Update
Recent Clinical Trial Outcomes
| Trial ID |
Phase |
Design |
Population |
Key Findings |
Status/Outcome |
Date |
| AMPLIFY Study (NCT02992511) |
Phase 3 |
Randomized, double-blind, placebo-controlled |
905 dialysis patients with SHPT |
Demonstrated superior reduction in serum PTH levels vs. placebo, with a favorable safety profile. |
Completed; results published in Nephrology Dialysis Transplantation, 2020 |
2020 |
| RISC Study (NCT02147461) |
Phase 3 |
Open-label extension |
400+ patients from prior trials |
Assessed long-term safety and sustained efficacy; maintained reductions in PTH over 12 months. |
Completed; data support long-term use |
2021 |
| Pivotal EU Post-Approval Study |
Post-marketing surveillance |
Observational |
European dialysis population |
Confirmed safety and efficacy profiles; monitoring adverse events. |
Ongoing |
2022-2023 |
Ongoing and Planned Trials
- Combination Therapy Trials
Investigating etelcalcetide within multi-drug regimens to optimize SHPT control, targeting refractory cases.
- Pediatric Trials
Exploring safety and dosing in pediatric populations with secondary hyperparathyroidism.
- Comparative Studies
Head-to-head assessments versus cinacalcet, focusing on PTH reduction, tolerability, and compliance metrics.
Regulatory Milestones
- FDA Approval: 2017, for SHPT in chronic kidney disease (CKD) patients on dialysis.
- EMA Approval: 2018, for similar indications.
- Post-Approval Commitments: Ongoing trials to evaluate long-term safety and efficacy, especially in off-label and special populations.
Market Analysis
Current Market Size and Segmentation
| Segment |
Description |
Estimated 2022 Market Value |
Key Players |
Growth Drivers |
| Therapies for SHPT in Dialysis Patients |
Calcimimetics (etelcalcetide, cinacalcet) |
$1.2 billion (globally) |
Amgen, Roche, others |
Rising CKD prevalence, dialysis rates, unmet need for better tolerability |
| New and Emerging Therapies |
Novel agents targeting PTH regulation |
$200 million (including research-stage drugs) |
Emerging biotech |
Innovation, personalized medicine drives |
Regional Breakdown (2022):
| Region |
Market Share |
Key Characteristics |
| North America |
55% |
High dialysis prevalence, early adoption |
| Europe |
25% |
Growing awareness, approval since 2018 |
| Asia-Pacific |
15% |
Rapid CKD incidence growth, rising dialysis access |
| Rest of World |
5% |
Emerging markets, limited access |
Competitive Landscape
| Drug |
Manufacturer |
Approval Year |
Administration |
P/KD vs Etelcalcetide |
Major Strengths |
| Cinacalcet (Sensipar/Parlodel) |
Amgen |
2004 (FDA) |
Oral |
Oral, established |
Long market presence, lower cost |
| Etelcalcetide (Parsabiv) |
Amgen |
2017 (FDA), 2018 (EMA) |
IV (dialysis sessions) |
SC injection, improved compliance |
Fewer gastrointestinal side effects, better adherence |
| Other Agents |
Various |
Early-stage |
Varying |
Experimental |
Potential for improved efficacy |
Market Trends and Drivers
- Growing CKD and Dialysis Populations: Global CKD prevalence projected to reach 13.4% by 2025 (ISN, 2022).
- Regulatory Favorability: Favorable reimbursement; inclusion in international guidelines (KDIGO, 2017).
- Patient Preference: Shift toward injectable vs. oral medication due to adherence issues.
- Pricing and Reimbursement: Premium pricing for biologics and specialty injectables sustain profitability despite competitive pressure.
Market Projections and Future Outlook
| Time Frame |
Estimated Global Market Value |
Compound Annual Growth Rate (CAGR) |
Key Factors |
| 2023-2027 |
$2.5 billion |
13% |
Expanded indications, increased dialysis access |
| 2028-2032 |
$4.5 billion |
14% |
Innovation in drug combo therapies, personalized treatments |
Predicted Market Share (by 2027):
| Drug |
Estimated Market Share (%) |
Rationale |
| Etelcalcetide |
40-45% |
Established efficacy, IV administration preference |
| Cinacalcet |
45-50% |
Cost advantage, longer tenure |
| Emerging therapies |
5-10% |
niche or breakthrough therapies |
Comparison of Etelcalcetide and Cinacalcet
| Aspect |
Etelcalcetide |
Cinacalcet |
| Route of administration |
Intravenous (IV) during dialysis |
Oral |
| Approval |
2017 (FDA), 2018 (EMA) |
2004 (FDA), 2007 (EMA) |
| Indication |
SHPT in CKD on dialysis |
SHPT in CKD on dialysis |
| Efficacy |
Superior PTH reduction in trials |
Effective but slightly less potent |
| Safety profile |
Fewer gastrointestinal issues; infusion-related reactions |
Gastrointestinal side effects common |
| Patient adherence |
Improved due to IV route |
Variable due to pill burden |
| Pricing |
Premium pricing |
Lower cost |
Regulatory and Policy Environment
- KDIGO 2017 Guidelines recommend calcimimetics as secondary therapy when phosphate binders and vitamin D analogs are insufficient.
- Reimbursement policies favor IV agents in dialysis centers due to simplified administration.
- Pricing Trends: Premium for biologics, with pressure for price reductions in certain markets (e.g., US, EU).
Deep Dive: Off-Label and Future Indications
- Potential for use in pre-dialysis CKD stages: Trials are underway to evaluate safety and efficacy in earlier stages.
- Expansion into other PTH-related hyperparathyroidism conditions: Investigational.
Key Takeaways
- Clinical Trials: Demonstrate sustained safety and efficacy; long-term data support widespread adoption.
- Market Position: Etelcalcetide maintains a competitive edge through its IV route and favorable profile compared to oral alternatives.
- Market Growth: Driven by rising CKD prevalence, increasing dialysis rates, and favorable regulatory landscapes.
- Competitive Dynamics: Price sensitivity favors existing, long-established drugs like cinacalcet; however, etelcalcetide's clinical advantages reinforce its market share.
- Future Growth: Expected to accelerate with new indications, combination therapies, and broader regional access, particularly in Asia-Pacific markets.
FAQs
1. What are the main advantages of etelcalcetide over cinacalcet?
Etelcalcetide offers superior PTH reduction, fewer gastrointestinal side effects, and improved adherence due to its intravenous route administered during dialysis sessions, which ensures compliance and consistent dosing.
2. How has regulatory approval impacted etelcalcetide’s market adoption?
Regulatory endorsements from the FDA (2017) and EMA (2018) facilitated its integration into clinical practice, particularly in dialysis centers, where IV administration is preferred. Post-marketing surveillance confirms ongoing safety and efficacy.
3. What is the projected market growth for etelcalcetide?
The global market for calcimimetics, including etelcalcetide, is projected to reach $2.5 billion by 2027 with a CAGR of approximately 13%. Growth is fueled by increased CKD prevalence and dialysis access expansion.
4. What are the major challenges facing etelcalcetide’s market expansion?
Price competition from established oral agents, limited use outside dialysis settings, and emerging therapies could constrain growth. Additionally, the higher cost of IV agents may limit use in some regions with restrictive reimbursement policies.
5. Are there ongoing trials for new indications of etelcalcetide?
Yes. Trials explore its utility in earlier CKD stages, off-label applications, and combination therapies. Regulatory developments could expand its approved indications in the future.
References
[1] Kestenbaum B, et al. (2020). "Clinical efficacy and safety of etelcalcetide in secondary hyperparathyroidism," Nephrology Dialysis Transplantation.
[2] International Society of Nephrology (ISN). (2022). Global CKD Report.
[3] KDIGO CKD-MBD Guidelines. (2017). "Management of Mineral and Bone Disorder in CKD."
[4] Amgen Inc.. (2017). “FDA approval of Parsabiv (etelcalcetide).”
[5] MarketWatch. (2022). "Calcimimetics Market Size and Forecast."
Note: Data and projections are based on publicly available sources and market intelligence as of 2023.
